Pacira BioSciences Reports Third-Quarter 2026 Financial Results
Pacira BioSciences announced its financial results for the third quarter of 2026, reporting $176.65 million in revenue and $0.70 in diluted earnings per share.
Stocks · News reference
8-K filing — Pacira BioSciences, Inc. (PCRX)
Filed: 2026-11-05 AccNo: 0001628280-26-071129 Size: 152 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Viatris Commences Tender Offer for Pacira BioSciences
Viatris Inc. has officially launched a cash tender offer to acquire all outstanding shares of Pacira BioSciences, Inc. for $36.50 per share.
Viatris Subsidiary Peach Purchaser Sub Commences Tender Offer To Acquire Pacira Biosciences For $36.50/Shr
PharmaCorp Rx Inc. to Present at Planet MicroCap Toronto 2026 Conference
PharmaCorp Rx Inc. announced that its senior management team will deliver a presentation at the upcoming Planet MicroCap Toronto 2026 Conference.
Top 3 Health Care Stocks That May Fall Off A Cliff In October
Option Care Health, Pacira Biosciences and HealthStream show overbought RSI levels above 83, warning momentum-focused investors.
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash at $36.50 per share, expected to close by end of 2026. The acquisition adds two marketed pain therapies (Exparel and Zilretta) generating $350.5 million in H1 2026 sales, plus a mid-stage gene therapy candidate (PCRX-201) for knee osteoarthritis. The deal is expected to be immediately accretive to Viatris' financial metrics and strengthen its non-opioid pain management portfolio.